Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan by Year
Pluvicto (lutetium Lu 177 vipivotide tetraxetan — PSMA radioligand therapy for mCRPC) ($M)
Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan: $1,994M in FY2025, up 43.2% from a year earlier.
Where the FY2025 figure comes from
“|| Pluvicto | 1 994 | 1 392 | 43 | 42”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pluvicto (lutetium Lu 177 vipivotide tetraxetan — PSMA radioligand therapy for mCRPC) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,994 | +43.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,392 | +42.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 980 | +261.6% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 271 | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Breakdown
What makes up pluvicto (lutetium Lu 177 vipivotide tetraxetan
Cite this data
StockData. (2026). Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.